Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

Name: Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
Published: 2021
License: Public Domain

Mayo Clinic · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

lymphoma

monoclonal b-cell lymphocytosis, chronic lymphocytic leukemia/small lymphocytic lymphoma, b-cell non hodgkin lymphoma, hodgkin lymphoma, lymphoma, covid-19 vaccine, cll, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

Related documents